摘要
目的观察依达拉奉联合醒脑静治疗急性重型颅脑损伤的临床疗效。方法60例急性重型颅脑损伤患者(GCS评分3～8分)随机分为治疗组和对照组各30例,两组均在常规治疗同时予依达拉奉30mg,2次/d静滴,共14d。治疗组同时合并使用醒脑静20mL,2次/d静滴,共14d。2周后观测两组患者APACHE-Ⅱ、GCS评分,伤后4个月进行总体疗效评价。结果治疗2周后,与对照组相比,治疗组APACHE-Ⅱ评分显著下降(P<0.01),GCS评分明显升高(P<0.05),伤后4个月总体疗效治疗组明显优于对照组(P<0.05)。结论依达拉奉联合醒脑静早期应用于重型颅脑损伤的治疗能有效改善神经功能缺失,提高临床疗效。
Objective To evaluate clinical efficacy in the treatment of acute serious cranioeerebral injury with Edaravone combined with Xingnaojing injection. Methods Sixty patients with acute serious craniocerebral injury（GCS 3-8） were divided to two groups randomly. One group were treated with Edaravone, and the other with Xingnaojing injection except Edaravone. APACHE-Ⅱ score and GCS score was observed two weeks after treatment and the therapeutic effect was surveyed four months after injury. Results Two weeks＇after treatments, APACHE-Ⅱ score was decreased significantly（P 〈 0.01 ）, GCS score rised significantly （P 〈 0.05 ）, and therapeutic effect four months after injury was better in therapy group（P〈 0.05）. Conclusion The program of Edaravone with Xingnaojing to treat acute serious craniocerebral injury can effectively improve the loss of neuro-functions and raise clinic therapeutic effect.
出处
《中国现代医生》
2009年第25期75-76,共2页
China Modern Doctor
关键词
依达拉奉
醒脑静注射液
急性重型颅脑损伤
Edaravone
Xingnaojing injection
Acute servere emniocerebral injury
